177 related articles for article (PubMed ID: 38382930)
1. Neoadjuvant therapies in resectable hepatocellular carcinoma: Exploring strategies to improve prognosis.
Ma YN; Jiang X; Song P; Tang W
Biosci Trends; 2024 Mar; 18(1):21-41. PubMed ID: 38382930
[TBL] [Abstract][Full Text] [Related]
2. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
3. New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials.
Jin H; Qin S; He J; Xiao J; Li Q; Mao Y; Zhao L
Int J Biol Sci; 2022; 18(7):2775-2794. PubMed ID: 35541908
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
Tovoli F; De Lorenzo S; Trevisani F
Vaccines (Basel); 2020 Oct; 8(4):. PubMed ID: 33023131
[TBL] [Abstract][Full Text] [Related]
5. Recent developments with immunotherapy for hepatocellular carcinoma.
Waidmann O
Expert Opin Biol Ther; 2018 Aug; 18(8):905-910. PubMed ID: 29995439
[TBL] [Abstract][Full Text] [Related]
6. Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma.
Zhang B; Yue J; Shi X; Cui K; Li L; Zhang C; Sun P; Zhong J; Li Z; Zhao L
BMJ Open; 2022 Sep; 12(9):e060955. PubMed ID: 36115673
[TBL] [Abstract][Full Text] [Related]
7. Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma.
Pourhamzeh M; Asadian S; Mirzaei H; Minaei A; Shahriari E; Shpichka A; Es HA; Timashev P; Hassan M; Vosough M
Mol Cell Biochem; 2023 Jan; 478(1):23-37. PubMed ID: 35708866
[TBL] [Abstract][Full Text] [Related]
8. The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials.
Ozer M; George A; Goksu SY; George TJ; Sahin I
Front Oncol; 2021; 11():801379. PubMed ID: 34956912
[TBL] [Abstract][Full Text] [Related]
9. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Bai J; Liang P; Li Q; Feng R; Liu J
Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in Hepatocellular Carcinoma.
Fulgenzi CAM; Talbot T; Murray SM; Silletta M; Vincenzi B; Cortellini A; Pinato DJ
Curr Treat Options Oncol; 2021 Aug; 22(10):87. PubMed ID: 34424422
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC).
Chiu LC; Lin SM; Lo YL; Kuo SC; Yang CT; Hsu PC
Vaccines (Basel); 2021 Jun; 9(7):. PubMed ID: 34201650
[TBL] [Abstract][Full Text] [Related]
12. Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma.
Chami P; Diab Y; Khalil DN; Azhari H; Jarnagin WR; Abou-Alfa GK; Harding JJ; Hajj J; Ma J; El Homsi M; Reyngold M; Crane C; Hajj C
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069095
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma.
Uson Junior PLS; Liu AJ; Sonbol MB; Borad MJ; Bekaii-Saab TS
Chin Clin Oncol; 2021 Feb; 10(1):11. PubMed ID: 33541088
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapies for advanced hepatocellular carcinoma.
Sun LY; Zhang KJ; Xie YM; Liu JW; Xiao ZQ
Front Pharmacol; 2023; 14():1138493. PubMed ID: 37025485
[TBL] [Abstract][Full Text] [Related]
15. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.
Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC
Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047
[TBL] [Abstract][Full Text] [Related]
16. Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC.
Marzi L; Mega A; Gitto S; Pelizzaro F; Seeber A; Spizzo G
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884392
[TBL] [Abstract][Full Text] [Related]
17. Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma.
Shrestha R; Prithviraj P; Anaka M; Bridle KR; Crawford DHG; Dhungel B; Steel JC; Jayachandran A
Front Oncol; 2018; 8():269. PubMed ID: 30057891
[TBL] [Abstract][Full Text] [Related]
18. Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma.
Zeng Z; Yang B; Liao ZY
Oncol Lett; 2020 Oct; 20(4):45. PubMed ID: 32802167
[TBL] [Abstract][Full Text] [Related]
19. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma.
Choi C; Yoo GS; Cho WK; Park HC
World J Gastroenterol; 2019 May; 25(20):2416-2429. PubMed ID: 31171886
[TBL] [Abstract][Full Text] [Related]
20. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
